Comparación entre CHOP-like y R-CHOP en pacientes con linfoma no Hodgkin difuso de grandes células B y folicular: 10 años de experiencia del Hospital de Clínicas de Montevideo, Uruguay

Background: The most common types of non-Hodgkin lymphoma (NHL) are diffuse large B cell (DLBCL) and follicular (FL). Aim: To analyze the benefit ofRituxi-mab in overall survival (OS) of patients with NHL. Material and Methods: Review of medical record of 230 adult patients with afirst episode of NH...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Oliver,Carolina, Guillermo,Cecilia, Martínez,Paula, Díaz,Lilián
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2013
Materias:	Lymphoma, follicular Lymphoma, large cell, immunoblastic Lymphoma, non-Hodgkin Rituximab
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013000700003
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872013000700003
record_format	dspace
spelling	oai:scielo:S0034-988720130007000032013-12-17Comparación entre CHOP-like y R-CHOP en pacientes con linfoma no Hodgkin difuso de grandes células B y folicular: 10 años de experiencia del Hospital de Clínicas de Montevideo, UruguayOliver,CarolinaGuillermo,CeciliaMartínez,PaulaDíaz,Lilián Lymphoma, follicular Lymphoma, large cell, immunoblastic Lymphoma, non-Hodgkin Rituximab Background: The most common types of non-Hodgkin lymphoma (NHL) are diffuse large B cell (DLBCL) and follicular (FL). Aim: To analyze the benefit ofRituxi-mab in overall survival (OS) of patients with NHL. Material and Methods: Review of medical record of 230 adult patients with afirst episode of NHL admitted between 2002 and 2011. We included 67 patients with DLBCL and 36 patients with FL. Results: The overall response (OR) was 64% with 39% complete remissions (CR) in DLBCL treated with CHOP-like and 100% with 89% CR with R-CHOP. The median OS with CHOP-like was 21 months versus not attained R-CHOP (p = 0.016). There was a statistically significant difference in median event-free survival (EvFS) in favor of R-CHOP: not attained versus 8.3 months for CHOP-like (log rank (p = 0.002)). In FL, the OR in patients treated with R-CHOP or R-CHOP-like was 85%) with 54% CR. With CHOP-like the OR was 59%> with 18% CR. The OS at 24 and 36 months in patients treated with R-CHOP or R-CHOP-like was 83 and 65%. The figures for patients treated with CHOP-like were 80 and 66%> respectively. The progression free survival (PFS) was 21 months with CHOP-like versus not attained with R-QT (p = 0,043). Conclusions: When Rituximab was added to CHOP, there was a higher CR, EvFS and OS in DLBCL and higher CR and PFS in FL.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.141 n.7 20132013-07-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013000700003es10.4067/S0034-98872013000700003
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Lymphoma, follicular Lymphoma, large cell, immunoblastic Lymphoma, non-Hodgkin Rituximab
spellingShingle	Lymphoma, follicular Lymphoma, large cell, immunoblastic Lymphoma, non-Hodgkin Rituximab Oliver,Carolina Guillermo,Cecilia Martínez,Paula Díaz,Lilián Comparación entre CHOP-like y R-CHOP en pacientes con linfoma no Hodgkin difuso de grandes células B y folicular: 10 años de experiencia del Hospital de Clínicas de Montevideo, Uruguay
description	Background: The most common types of non-Hodgkin lymphoma (NHL) are diffuse large B cell (DLBCL) and follicular (FL). Aim: To analyze the benefit ofRituxi-mab in overall survival (OS) of patients with NHL. Material and Methods: Review of medical record of 230 adult patients with afirst episode of NHL admitted between 2002 and 2011. We included 67 patients with DLBCL and 36 patients with FL. Results: The overall response (OR) was 64% with 39% complete remissions (CR) in DLBCL treated with CHOP-like and 100% with 89% CR with R-CHOP. The median OS with CHOP-like was 21 months versus not attained R-CHOP (p = 0.016). There was a statistically significant difference in median event-free survival (EvFS) in favor of R-CHOP: not attained versus 8.3 months for CHOP-like (log rank (p = 0.002)). In FL, the OR in patients treated with R-CHOP or R-CHOP-like was 85%) with 54% CR. With CHOP-like the OR was 59%> with 18% CR. The OS at 24 and 36 months in patients treated with R-CHOP or R-CHOP-like was 83 and 65%. The figures for patients treated with CHOP-like were 80 and 66%> respectively. The progression free survival (PFS) was 21 months with CHOP-like versus not attained with R-QT (p = 0,043). Conclusions: When Rituximab was added to CHOP, there was a higher CR, EvFS and OS in DLBCL and higher CR and PFS in FL.
author	Oliver,Carolina Guillermo,Cecilia Martínez,Paula Díaz,Lilián
author_facet	Oliver,Carolina Guillermo,Cecilia Martínez,Paula Díaz,Lilián
author_sort	Oliver,Carolina
title	Comparación entre CHOP-like y R-CHOP en pacientes con linfoma no Hodgkin difuso de grandes células B y folicular: 10 años de experiencia del Hospital de Clínicas de Montevideo, Uruguay
title_short	Comparación entre CHOP-like y R-CHOP en pacientes con linfoma no Hodgkin difuso de grandes células B y folicular: 10 años de experiencia del Hospital de Clínicas de Montevideo, Uruguay
title_full	Comparación entre CHOP-like y R-CHOP en pacientes con linfoma no Hodgkin difuso de grandes células B y folicular: 10 años de experiencia del Hospital de Clínicas de Montevideo, Uruguay
title_fullStr	Comparación entre CHOP-like y R-CHOP en pacientes con linfoma no Hodgkin difuso de grandes células B y folicular: 10 años de experiencia del Hospital de Clínicas de Montevideo, Uruguay
title_full_unstemmed	Comparación entre CHOP-like y R-CHOP en pacientes con linfoma no Hodgkin difuso de grandes células B y folicular: 10 años de experiencia del Hospital de Clínicas de Montevideo, Uruguay
title_sort	comparación entre chop-like y r-chop en pacientes con linfoma no hodgkin difuso de grandes células b y folicular: 10 años de experiencia del hospital de clínicas de montevideo, uruguay
publisher	Sociedad Médica de Santiago
publishDate	2013
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872013000700003
work_keys_str_mv	AT olivercarolina comparacionentrechoplikeyrchopenpacientesconlinfomanohodgkindifusodegrandescelulasbyfolicular10anosdeexperienciadelhospitaldeclinicasdemontevideouruguay AT guillermocecilia comparacionentrechoplikeyrchopenpacientesconlinfomanohodgkindifusodegrandescelulasbyfolicular10anosdeexperienciadelhospitaldeclinicasdemontevideouruguay AT martinezpaula comparacionentrechoplikeyrchopenpacientesconlinfomanohodgkindifusodegrandescelulasbyfolicular10anosdeexperienciadelhospitaldeclinicasdemontevideouruguay AT diazlilian comparacionentrechoplikeyrchopenpacientesconlinfomanohodgkindifusodegrandescelulasbyfolicular10anosdeexperienciadelhospitaldeclinicasdemontevideouruguay
_version_	1718436698721878016

Comparación entre CHOP-like y R-CHOP en pacientes con linfoma no Hodgkin difuso de grandes células B y folicular: 10 años de experiencia del Hospital de Clínicas de Montevideo, Uruguay

Ejemplares similares